Human embryonic stem cell-derived mesenchymal stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma

• Published in: Human gene therapy Vol. 22; no. 11; p. 1365
• Main Authors: Bak, Xiao Ying, Lam, Dang Hoang, Yang, Jingye, Ye, Kai, Wei, Esther Lee Xing, Lim, Sai Kiang, Wang, Shu
• Format: Journal Article
• Language: English
• Published: United States 01.11.2011
• Subjects: Animals; Baculoviridae - genetics; Cell Line, Tumor; Cell Movement; Embryonic Stem Cells - cytology; Feasibility Studies; Ganciclovir - therapeutic use; Genetic Vectors; Glioblastoma - genetics; Glioblastoma - therapy; Herpesviridae; Humans; Lentivirus - genetics; Male; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - physiology; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Prodrugs - administration & dosage; Thymidine Kinase - genetics; Viral Proteins - genetics
• ISSN: 1557-7422
• DOI: 10.1089/hum.2010.212

Mesenchymal stem cells (MSCs) possess tumor-tropic properties and consequently have been used to deliver therapeutic agents for cancer treatment. Their potential in cancer therapy highlights the need for a consistent and renewable source for the production of uniform human MSCs suitable for clinical applications. In this study, we seek to investigate whether human embryonic stem cells can be used as a cell source to fulfill this goal. We generated MSC-like cells from two human embryonic stem cell lines, HuES9 and H1, and observed that MSC-like cells derived from human embryonic stem cells were able to migrate into human glioma intracranial xenografts after being injected into the cerebral hemisphere contralateral to the tumor inoculation site. We engineered these cells with baculoviral and lentiviral vectors, respectively, for transient and stable expression of the herpes simplex virus thymidine kinase gene. In tumor-bearing mice the engineered MSC-like cells were capable of inhibiting tumor growth and prolonging survival in the presence of ganciclovir after they were injected either directly into the xenografts or into the opposite hemisphere. Our findings suggest that human embryonic stem cell-derived MSCs may be a viable and attractive alternative for large-scale derivation of targeting vehicles for cancer therapy.